Parkinson’s disease (PD) is the second most common neurodegenerative disorder, yet early and accurate diagnosis remains a challenge. Blood-based biomarkers offer a minimally invasive solution to detect and monitor PD, paving the way for improved patient outcomes and accelerated drug development.

Download our latest application note, “Advancing Parkinson’s Disease Research: The Role of Blood-Based Biomarkers,” to explore:

• The urgent need for reliable PD biomarkers and their role in early detection
• Key biomarkers, including alpha-synuclein (α-syn), NfL, GFAP, and inflammatory markers
• How ultra-sensitive Simoa® technology enables precise biomarker quantification in blood
• The impact of blood biomarkers on drug development and patient stratification

Gain Insights from Cutting-Edge Biomarker Research
Learn how the latest advancements in biomarker detection can transform Parkinson’s disease research and clinical care. Download the application note now to stay at the forefront of innovation.

Download the app note to learn more